COMMUNIQUÉS West-GlobeNewswire

Medtronic Completes Sale of a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health

31/07/2017 - 01:00

DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses [...]

Le Groupe Medasys annonce l'acquisition ce jour de la société Netika SAS

28/07/2017 - 18:25

Clamart, le 28 juillet 2017 - Medasys, principal éditeur et intégrateur français de logiciels médicaux pour établissements de santé, publics et privés, dans les domaines du dossier patient, de la production de soins et [...]

SPINEWAY : Renforcement de la structure bilancielle par émission réservée d'ORNANE assorties de BSA

28/07/2017 - 18:00

SPINEWAY Renforcement de la structure bilancielle par émission réservée d'ORNANE assorties de BSA Spineway, spécialiste des implants et ancillaires chirurgicaux pour le traitement des pathologies de la colonne [...]

SPINEWAY : Reinforcement of the balance-sheet structure with a reserved issue of Notes with Warrants

28/07/2017 - 18:00

SPINEWAY Reinforcement of the balance-sheet structure with a reserved issue of Notes with Warrants Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), announces [...]

Oriola Corporation - Repurchase of own shares on 28 July 2017

28/07/2017 - 17:45

ORIOLA CORPORATION STOCK EXCHANGE RELEASE 28 JULY 2017 AT 18:45 EEST In the Nasdaq Helsinki Date 28 July 2017 Exchange transaction Buy Share trading code OKDBV Amount, shares 10.681 Average price/share, EUR 3,6109 Total [...]

Abiomed annonce un chiffre d'affaires au T1 de l'exercice financier 2018 de 132,5 millions de dollars, en progression de 29 % par rapport à l'année précédente

28/07/2017 - 15:43

La société annonce le remboursement japonais pour les pompes cardiaques Impella® et augmente la fourchette inférieure de ses prévisions relatives au chiffre d'affaires pour l'exercice financier 2018 DANVERS, [...]

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

28/07/2017 - 14:00

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region Funding will support the clinical development of the Company's lead innovative immuno-oncology drug Gosselies, Belgium - July 28, [...]

U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron

28/07/2017 - 13:01

UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]

DBV Technologies Résultats financiers du premier semestre 2017

28/07/2017 - 07:30

Communiqué de Presse Montrouge, France, le 28 juillet 2017 (7H30 CEST) DBV Technologies Résultats financiers du premier semestre 2017 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT), société [...]

DBV Technologies Reports First Half 2017 Financial Results

28/07/2017 - 07:30

Press Release Montrouge, France, July 28, 2017 DBV Technologies Reports First Half 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today reported first half 2017 [...]

ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

28/07/2017 - 07:00

Press release PDF This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Navamedic ASA: Second quarter results 2017

28/07/2017 - 07:00

Oslo, 28 July 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 89.7 million in the second quarter of 2017 (NOK 66.7 million in Q2 2016), representing a growth of 34.4%, following the successful ramp-up of the [...]

Essilor - Communiqué : Une performance résiliente au premier semestre

28/07/2017 - 06:30

Une performance résiliente au premier semestre Version PDF du communiqué Hausse de 9,1 % du chiffre d'affaires, dont 6,9 % hors change Meilleure dynamique en Amérique du Nord, bonne performance de l'Europe Pays à forte [...]

Essilor - News Release: Resilient First Half

28/07/2017 - 06:30

Resilient First Half PDF Version of the news release Revenue growth of 9.1% and 6.9% in constant currency Improving momentum in North America, good performance in Europe Fast-Growing Markets impacted by a decline in [...]

Essilor : Mise à disposition du rapport financier semestriel 2017

28/07/2017 - 06:30

Mise à disposition du rapport financier semestriel 2017 Charenton-le-Pont, France (le 28 juillet 2017 - 6h30) - Essilor International publie ce matin son rapport financier semestriel 2017. Ce document comprend les [...]

Essilor: Publication of the 2017 Interim Financial Report

28/07/2017 - 06:30

Publication of the 2017 Interim Financial Report Charenton-le-Pont, France (July 28, 2017 - 6:30 am) - The Essilor International 2017 Interim Financial Report is being published today. The report comprises the interim [...]

Solid financials support R&D progress

27/07/2017 - 22:01

Solid financials support R&D progress This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are [...]

Servier licenses GLPG1972 in osteoarthritis from Galapagos

27/07/2017 - 22:00

Servier licenses GLPG1972 in osteoarthritis This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are [...]

Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events

27/07/2017 - 18:32

Bagsværd, Denmark, 27 July 2017 - The European Commission has approved an update to the Victoza ® (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events [...]